September 17, 2015

"Don't you love the way companies find you and spam you daily the moment you make a sideways glance towards one of their products?" Indrani Stangl asks us. It's a good question. It's all too easy to get sucked into a newsletter situation. Some of them are good, many of them are all kinds of blight. Here, Stangl goes deeper into the unsubcribe dilemma.

My inbox, like everyone else's, is brimming with newsletters, offers, coupons, and other nonsense. Why I would take the time to read a newsletter by a staffer at 'Nothing Bundt Cakes' (don't get me started on ridiculous company names) or the place I purchased dog poop bags from, is beyond me. Generally speaking I filter these directly into my trash file, but every once in a while, enough is enough. I take the time to click the 'unsubscribe' link that is in .00001 type at the very bottom of their message.

Then starts the drill....read more
By Josh Tyson | UX Magazine

             

Full Article

The police arrested a man absconded from the Government Medical College Hospital, Alappuzha, and was trying to cross into Tamil Nadu through the distr

There will be several changes to existing working norms and guidelines that organisations will need to abide by in order to ensure safety at the workplace, says the report

Which category does your business belong to?

A digital shop-floor with specific interventions on planning and execution will become the new normal, says EY India Partner and Automotive Sector Leader Vinay Raghunath

The asymmetric unit of the centrosymmetric title salt solvate, 2C17H17F6N2O+· C4H4O42−·CH3CH2OH, (systematic name: 2-{[2,8-bis­(tri­fluoro­meth­yl)quinolin-4-yl](hy­droxy)meth­yl}piperidin-1-ium butane­dioate ethanol monosolvate) comprises two independent cations, with almost superimposable conformations and each approximating the shape of the letter L, a butane­dioate dianion with an all-trans conformation and an ethanol solvent mol­ecule. In the crystal, supra­molecular chains along the a-axis direction are sustained by charge-assisted hy­droxy-O—H⋯O(carboxyl­ate) and ammonium-N—H⋯O(carboxyl­ate) hydrogen bonds. These are connected into a layer via C—F⋯π(pyrid­yl) contacts and π–π stacking inter­actions between quinolinyl-C6 and –NC5 rings of the independent cations of the asymmetric unit [inter-centroid separations = 3.6784 (17) and 3.6866 (17) Å]. Layers stack along the c-axis direction with no directional inter­actions between them. The analysis of the calculated Hirshfeld surface reveals the significance of the fluorine atoms in surface contacts. Thus, by far the greatest contribution to the surface contacts, i.e. 41.2%, are of the type F⋯H/H⋯F and many of these occur in the inter-layer region. However, these contacts occur at separations beyond the sum of the van der Waals radii for these atoms. It is noted that H⋯H contacts contribute 29.8% to the overall surface, with smaller contributions from O⋯H/H⋯O (14.0%) and F⋯F (5.7%) contacts.

Serial rotation electron diffraction (SerialRED) has been developed as a fully automated technique for three-dimensional electron diffraction data collection that can run autonomously without human intervention. It builds on the previously established serial electron diffraction technique, in which submicrometre-sized crystals are detected using image processing algorithms. Continuous rotation electron diffraction (cRED) data are collected on each crystal while dynamically tracking the movement of the crystal during rotation using defocused diffraction patterns and applying a set of deflector changes. A typical data collection screens up to 500 crystals per hour, and cRED data are collected from suitable crystals. A data processing pipeline is developed to process the SerialRED data sets. Hierarchical cluster analysis is implemented to group and identify the different phases present in the sample and to find the best matching data sets to be merged for subsequent structure analysis. This method has been successfully applied to a series of zeolites and a beam-sensitive metal–organic framework sample to study its capability for structure determination and refinement. Two multi-phase samples were tested to show that the individual crystal phases can be identified and their structures determined. The results show that refined structures obtained using automatically collected SerialRED data are indistinguishable from those collected manually using the cRED technique. At the same time, SerialRED has lower requirements of expertise in transmission electron microscopy and is less labor intensive, making it a promising high-throughput crystal screening and structure analysis tool.

Serial crystallography has enabled the study of complex biological questions through the determination of biomolecular structures at room temperature using low X-ray doses. Furthermore, it has enabled the study of protein dynamics by the capture of atomically resolved and time-resolved molecular movies. However, the study of many biologically relevant targets is still severely hindered by high sample consumption and lengthy data-collection times. By combining serial synchrotron crystallography (SSX) with 3D printing, a new experimental platform has been created that tackles these challenges. An affordable 3D-printed, X-ray-compatible microfluidic device (3D-MiXD) is reported that allows data to be collected from protein microcrystals in a 3D flow with very high hit and indexing rates, while keeping the sample consumption low. The miniaturized 3D-MiXD can be rapidly installed into virtually any synchrotron beamline with only minimal adjustments. This efficient collection scheme in combination with its mixing geometry paves the way for recording molecular movies at synchrotrons by mixing-triggered millisecond time-resolved SSX.

Electron microscopy of macromolecular structures is an approach that is in increasing demand in the field of structural biology. The automation of image acquisition has greatly increased the potential throughput of electron microscopy. Here, the focus is on the possibilities in Scipion to implement flexible and robust image-processing workflows that allow the electron-microscope operator and the user to monitor the quality of image acquisition, assessing very simple acquisition measures or obtaining a first estimate of the initial volume, or the data resolution and heterogeneity, without any need for programming skills. These workflows can implement intelligent automatic decisions and they can warn the user of possible acquisition failures. These concepts are illustrated by analysis of the well known 2.2 Å resolution β-galactosidase data set.

Funded by BP through the Florida Institute of Oceanography, the scientists will make the 10-day trip aboard the institute’s 115-foot research vessel. The divers, scientists and photographers will document hard bottoms of Florida, from the Keys to the Panhandle, to gain a better understanding of these sponge- and coral-dominated communities

The post Gulf of Mexico survey will benchmark diversity of ocean floor appeared first on Smithsonian Insider.

As researchers investigate the impact of the Burmese python in the Everglades, scientists from the Smithsonian Institution, South Florida Natural Resources Center and the University of Florida examined the snake’s predation of the area’s birds. They found that birds, including endangered species, accounted for 25 percent of the python’s diet in the Everglades.

The post Invasive Burmese pythons are taking a toll on Florida’s native birds appeared first on Smithsonian Insider.

A team of scientists from the Smithsonian Environmental Research Center in Edgewater, Md., is taking a closer look at how rising acidification of ocean water may be impacting estuaries and near shore environments on the Chesapeake Bay

The post Oysters on floating plates help scientists study acidification and shell growth appeared first on Smithsonian Insider.

Depending on where the fish disperse from, the use of ‘stepping stones', flotsam or simply being an adult can help in the journey to find a new home.

The post Ability to raft with flotsam and use non-reef habitats helps tropical fish journey to new places, study finds appeared first on Smithsonian Insider.

A box jellyfish from the Caribbean appears to have recently become established in the red mangroves of Florida near Boca Raton.

The post Caribbean box jellyfish now thriving in southern Florida appeared first on Smithsonian Insider.

The snakes are not only eating the area’s birds, but also the birds’ eggs straight from the nest.

The post Invasive pythons in Florida now stealing bird eggs straight from the nest appeared first on Smithsonian Insider.

Fond of a range of marine and freshwater vegetation such as turtle grass and eelgrass, the Florida manatee spends most of its waking hours grazing […]

The post Algae bloom toxins may make Florida’s manatees and sea turtles susceptible to deadly accidents appeared first on Smithsonian Insider.

As economic expansion and development fragments the forest landscape of central India, the species that rely on that habitat—including endangered tigers and leopards—face dwindling populations […]

The post Forest corridors essential to gene flow in India’s leopard and tiger populations appeared first on Smithsonian Insider.

Roses, carnations and lilies are today among the most popular flowers people use to express sympathy and condolence. The simple act of sending flowers to […]

The post Funeral flowers in the Stone Age: Q&A with Smithsonian anthropologist Reuven Yeshurun appeared first on Smithsonian Insider.

Identifying larval stages of marine fishes in the open ocean is difficult because the young fishes often bear little or no resemblance to the adults […]

The post Smithsonian scientists link fish larva in Florida to new sea bass species from Curacao appeared first on Smithsonian Insider.

Their flavor is a unique blend of lobster and shrimp say lovers of the savory South American crustaceans called “langostinos.” Simmered with garlic, lime juice, […]

The post Squat lobsters: colorful kings of the ocean floor appeared first on Smithsonian Insider.

The odds of being attacked and castrated by a variety of parasitic flatworms increases for marine horn snails the farther they are found from the […]

The post Parasitic flatworms flout global biodiversity patterns appeared first on Smithsonian Insider.

Scientists from the Smithsonian and the University of Rhode Island have found unsuspected linkages between the oxidation state of iron in volcanic rocks and variations […]

The post Scientists uncover relationship between lavas erupting on sea floor and deep-carbon cycle appeared first on Smithsonian Insider.

Structural investigations of amorphous and nanocrystalline phases forming in solution are historically challenging. Few methods are capable of in situ atomic structural analysis and rigorous control of the system. A mixed-flow reactor (MFR) is used for total X-ray scattering experiments to examine the short- and long-range structure of phases in situ with pair distribution function (PDF) analysis. The adaptable experimental setup enables data collection for a range of different system chemistries, initial supersaturations and residence times. The age of the sample during analysis is controlled by adjusting the flow rate. Faster rates allow for younger samples to be examined, but if flow is too fast not enough data are acquired to average out excess signal noise. Slower flow rates form older samples, but at very slow speeds particles settle and block flow, clogging the system. Proper background collection and subtraction is critical for data optimization. Overall, this MFR method is an ideal scheme for analyzing the in situ structures of phases that form during crystal growth in solution. As a proof of concept, high-resolution total X-ray scattering data of amorphous and crystalline calcium phosphates and amorphous calcium carbonate were collected for PDF analysis.

The post Learn about the National Zoo’s flamingo flock with keeper Sara Hallager appeared first on Smithsonian Insider.

The post Conrad Labandiera, Smithsonian palentologist, studies fossils to learn how insects got along before flowering plants arrived appeared first on Smithsonian Insider.

Jessica Lunt, Postdoctoral Fellow at the Smithsonian Marine Station in Fort Pierce, Fla., shows how her oyster sampling fieldwork looks at what lives on these […]

The post Florida Oyster Reef Communities appeared first on Smithsonian Insider.

Flowers are usually associated with butterflies, but not the Dutchman’s Pipe (Aristolochia grandiflora). This deciduous vine, native to Brazil, has large flowers that emit an odor of decaying flesh, which attracts flies and beetles.

The post Video: Smithsonian horticulturalist Janet Draper discusses the pollination of the pelican flower appeared first on Smithsonian Insider.

Candy Feller, senior ecologist at the Smithsonian Environmental Research Center in Edgewater, Md., will lead an effort to track more than 100 miles of Florida mangrove forests that are encroaching on salt marshes to the north.

The post NASA to help Smithsonian botanists track northern creep of Florida mangroves appeared first on Smithsonian Insider.

Recent botanical exploration efforts in the rugged Marquesas Islands (French Polynesia) have increased the known flora of the archipelago by an impressive 20 percent. Field research and collecting in conjunction with the Vascular Flora of the Marquesas Islands and Flore de la Polynesie française projects have yielded 62 new species of ferns and flowering plants bringing the total native species to 360, of which 18 are newly described and illustrated in a special issue of PhytoKeys.

The post Marquesas Islands in French Polynesia yield 18 new species of rare ferns and flowering plants appeared first on Smithsonian Insider.

Fulcaldea stuessyi is a newly discovered member of the Barnadesioideae, a subfamily of the Compositae, or sunflower family of flowering plants. It was found in northeastern […]

The post Fulcaldea stuessyi is newly discovered member of the Barnadesioideae, a subfamily of the Compositae, or sunflower family of flowering plants, appeared first on Smithsonian Insider.

What plant species has just been discovered but is almost gone? Bidens meyeri–a just discovered flowering plant from the small South Pacific island of Rapa, […]

The post New South Pacific cliff flower is critically endangered appeared first on Smithsonian Insider.

Rattlesnake, zebra and peacock plants have a new wild relative, discovered by Rodolfo Flores, Panamanian botanist and intern at the Smithsonian Tropical Research Institute (STRI). […]

The post Smithsonian Botanist Discovers New Ground-Flowering Plant in Panama appeared first on Smithsonian Insider.

Fort Pierce, Fla. – Fall in southern Florida is festival season: when the weather stops being oppressively hot and 70 degrees is positively autumnal.  On […]

The post Annual Smithsonian-led science festival draws crowds in Fort Pierce, Florida appeared first on Smithsonian Insider.

Source: Streetwise Reports   05/05/2020

Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ), which focuses on blood-related disorders, and global biopharmaceuticals firm Alexion Pharmaceuticals Inc. (ALXN:NASDAQ) announced that they have entered into a definitive merger agreement for Portola to be acquired by Alexion.

The acquisition is said to provide a key addition to Alexion's diversified commercial portfolio. The report indicated that the merger agreement has already been unanimously approved each of the company's boards of directors.

The report explained that "Portola's commercialized medicine, Andexxa^® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya^® in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding."

Portola's President and CEO Scott Garland commented, "In developing and launching Andexxa, Portola has established a strong foundation for changing the standard of care for patients receiving Factor Xa inhibitors that experience a major, life-threatening bleed. Andexxa rapidly reverses the pharmacologic effect of rivaroxaban and apixaban within two minutes, reducing anti-Factor Xa activity by 92 percent...Given their enhanced resources, global footprint and proven commercial expertise, we look forward to working with Alexion to maximize the value of Andexxa. With their commitment to commercial excellence, together, we will be able to drive stronger utilization of Andexxa, increase penetration and accelerate adoption in the critical care setting."

Ludwig Hantson, Ph.D., CEO of Alexion, remarked, "The acquisition of Portola represents an important next step in our strategy to diversify beyond C5. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care...We believe Andexxa has the potential to become the global standard of care for patients who experience life-threatening bleeds while taking Factor Xa inhibitors apixaban and rivaroxaban. By leveraging Alexion's strong operational and sales infrastructure and deep relationships in hospital channels, we are well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders."

The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. The purchase is subject to approval by a majority interest of Portola's common stockholders tendering their shares along with ordinary closing conditions and regulatory approvals. The company noted that "following successful completion of the tender offer, Alexion will acquire all remaining shares not tendered in the offer at the same price of $18 per share through a merger."

Alexion is a global biopharmaceutical company based in Boston, Mass., with offices in 50 countries worldwide. The company states that it has been "the global leader in complement biology and inhibition for more than 20 years and that it has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder."

Portola is headquartered in South San Francisco, Calif., and is a commercial-stage biopharmaceutical company focused on treating patients with serious blood-related disorders. Specifically, the company is engaged in developing and commercializing novel therapeutics in order to advance the fields of thrombosis and other hematologic conditions. The firm listed that its first two commercialized products are Andexxa^® and Bevyxxa^® (betrixaban), and that it is also advancing and developing cerdulatinib, a SYK/JAK inhibitor for use in treatment of hematologic cancers.

Portola Pharmaceuticals started off the day with a market capitalization of around $609.0 million with approximately 78.5 million shares outstanding and a short interest of about 23.0%. PTLA shares opened 130% higher today at $17.85 (+$10.09, +130.03%) over yesterday's $7.85 closing price. The stock has traded today between $17.71 and $17.91 per share and is currently trading at $17.83 (+$10.07, +129.77%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

A single breakthrough discovery for managing citrus greening in Florida in the future is unlikely, says a new report by the National Academies of Sciences, Engineering, and Medicine.

Urban flooding is a complex and distinct kind of flooding, compounded by land use and high population density, and it requires a different approach to assess and manage, says Framing the Challenge of Urban Flooding in the United States, a new report from the National Academies of Sciences, Engineering, and Medicine.

Flowbird Group has announced recent developments that limit...

A spike in texts and calls to crisis hotlines reflects Americans' growing anxiety about the coronavirus and its impact on their lives.; Credit: Richard Bailey/Getty Images

Normally, Laura Mayer helps the most acutely suicidal callers find the nearest hospital emergency room. But in a pandemic, that has become a crisis counselor's advice of last resort.

"It's a difficult decision because we do know that by sending them into an overburdened health care system, they may or may not get the treatment that they need," says Mayer, who is director of PRS CrisisLink in Oakton, Va., which also takes calls for the National Suicide Prevention Lifeline. "The resources may or may not be there, and we're exposing them to the illness."

So instead, counselors are devoting more time to each caller, offering ad hoc therapy and coaxing them to talk through their pain. These days, that pain often has many sources: lost jobs, severed relationships and sick family.

"The type of call and the seriousness of the call is very different this year than it was in previous years," Mayer says. "There's environmental issues, internal issues, family issues. ... It's never one thing."

America's crisis centers and hotlines are themselves in crisis. As people grapple with fear, loneliness and grief, on a grand scale, those stresses are showing up at crisis hotlines. Not only are the needs greater, but their clients' problems are more acute and complex and offer a window into the emotional struggles Americans face.

Across the board, hotlines of all kinds are reporting increases in volume.

The Substance Abuse and Mental Health Services Administration saw a fivefold increase at its National Helpline in March. The Crisis Text Line says its volumes are up 40% in the pandemic, to about 100,000 conversations a month.

Volunteer counselors and good Samaritans are responding by lining up to help.

But Mayer says the heaviness takes its toll. Those offering this kind of support end up needing support themselves.

"This illness is starting to impact each of our crisis workers and counselors themselves personally," she says. "So everyone is kind of a client right now, and that's been really challenging."

Nancy Lublin, CEO and co-founder of the Crisis Text Line, says she is bracing for sustained need. "This echo of the physical virus, the mental health echo, we fear it's going to last a very long time and that the intensity will remain," she says.

Over the last two months, the focal point of the emotional pain has shifted, she says. Initially, the spike in traffic was over anxiety about the virus itself. That shifted to complaints of isolation. Now, texters talk of depression and grief.

"So we've doubled the number of conversations that are about grief, and there the top two words that we see are 'grandma' and 'grandpa,' " she says.

And it's no longer just young people texting. Adults are complaining of loneliness, sexual abuse and eating disorders.

"As the quarantines go on and continue, we're seeing it's the people over the age of 35 who are increasing at a higher percentage of our volume," Lublin says. "For the first time, we're seeing people over the age of 60 texting us."

Texting is an ideal medium, she says, for those stuck at home with no personal space: "You don't have to find a quiet space where no one else can hear you."

And for some, that might be the only form of escape. The text line has seen a 74% increase in references to domestic violence. "We see words like 'trapped' [and] 'hurt,' " says Lublin.

Many shelters have shut down, and some of those in-person centers, including the Salvation Army in Philadelphia, now rely on their own hotlines instead.

Arielle Curry, director of the Salvation Army's anti-human trafficking program, says many of her clients can't afford cell phones and have lost touch; those who remain in contact are in dire straits, searching for a shorter supply of money or drugs, and are often suicidal. Curry says addressing those acute emotional needs by phone is frustrating; sometimes she doesn't even know where they are and can't send help to intervene.

"You can't ... comfort someone and look them in their eyes and support them face-to-face," she says. That makes it hard, Curry says, not to feel helpless and hopeless herself.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Patt Morrison's ensemble for Aug 8, 2013.; Credit: Dave Coelho/KPCC

What shall we call this color scheme? How about ‘Manhattan Mermaid’?

The petrel blues, the turquoises, the aquas – and then that uptown/downtown black, in this case a black linen duster over a Peter Max-style splashy-print silk dress. The way the hem pools at the sides a bit reminds me of the cut of Pre-Raphaelite ladies’ tunics; I’d love to dress “period” for a week to see whether I’d like it.

Imagine, a week of hoop skirts … a week of 1950s tailleurs … a week of bustles … a week of hobble skirts … a week of liberated Pre-Raphaelite velvet gowns!

The hat is so unmistakably summer in fabric and color that it doesn’t get out of the hatbox as much as it should, poor thing. And the shoes – I did not get them together, honest, but even though the prints don’t match, it’s the dissonance that makes them work better together than if they had.

The fabric is a very textured canvas and printed like batik. [They are not the soul of comfort – oh what a dreadful pun, but is there any other kind of pun? – but they look smart hooked over the railing of a chair in a chic bistro, which is where I intend to take them!]

And the bracelets, one from a great-aunt who had a fine eye for jewelry – the turquoise is almost Persian, it’s so green, but it’s more likely to be American. The cuff is definitely Southwest, with the rope-pattern trim and the irregularly shaped bezels, although the turquoises themselves are symmetrical.

Because I’m left-handed, my right arm bears the singular honor of being “ornamental,” and bearing the burden of the bling.

Summer on, ladies!

This content is from Southern California Public Radio. View the original story at SCPR.org.

Scientists have produced a list of seafloor characteristics to determine the health status of the ecosystem it supports. These indicators could improve the quality and consistency of marine conservation efforts across Europe, particularly where the impact of human activities is high.

Some Marine and Coastal have been altered over long periods of time, resulting in a loss of knowledge of their true healthy state, new research suggests. In this UK study, researchers used historical records, samples of sediment and present-day diving surveys to reconstruct the true history of shellfish beds on the east coast of Scotland.

The effects of seafloor trawling can extend further than the immediate fishing grounds, affecting delicate deep-sea ecosystems, new research suggests. In this Mediterranean study, the researchers demonstrated that clouds of sediment from trawling reached deeper habitats, increasing water-borne sediment particle concentrations to a hundred times that of background levels.

Source: Streetwise Reports   05/05/2020

Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ), which focuses on blood-related disorders, and global biopharmaceuticals firm Alexion Pharmaceuticals Inc. (ALXN:NASDAQ) announced that they have entered into a definitive merger agreement for Portola to be acquired by Alexion.

The acquisition is said to provide a key addition to Alexion's diversified commercial portfolio. The report indicated that the merger agreement has already been unanimously approved each of the company's boards of directors.

The report explained that "Portola's commercialized medicine, Andexxa^® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya^® in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding."

Portola's President and CEO Scott Garland commented, "In developing and launching Andexxa, Portola has established a strong foundation for changing the standard of care for patients receiving Factor Xa inhibitors that experience a major, life-threatening bleed. Andexxa rapidly reverses the pharmacologic effect of rivaroxaban and apixaban within two minutes, reducing anti-Factor Xa activity by 92 percent...Given their enhanced resources, global footprint and proven commercial expertise, we look forward to working with Alexion to maximize the value of Andexxa. With their commitment to commercial excellence, together, we will be able to drive stronger utilization of Andexxa, increase penetration and accelerate adoption in the critical care setting."

Ludwig Hantson, Ph.D., CEO of Alexion, remarked, "The acquisition of Portola represents an important next step in our strategy to diversify beyond C5. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care...We believe Andexxa has the potential to become the global standard of care for patients who experience life-threatening bleeds while taking Factor Xa inhibitors apixaban and rivaroxaban. By leveraging Alexion's strong operational and sales infrastructure and deep relationships in hospital channels, we are well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders."

The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. The purchase is subject to approval by a majority interest of Portola's common stockholders tendering their shares along with ordinary closing conditions and regulatory approvals. The company noted that "following successful completion of the tender offer, Alexion will acquire all remaining shares not tendered in the offer at the same price of $18 per share through a merger."

Alexion is a global biopharmaceutical company based in Boston, Mass., with offices in 50 countries worldwide. The company states that it has been "the global leader in complement biology and inhibition for more than 20 years and that it has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder."

Portola is headquartered in South San Francisco, Calif., and is a commercial-stage biopharmaceutical company focused on treating patients with serious blood-related disorders. Specifically, the company is engaged in developing and commercializing novel therapeutics in order to advance the fields of thrombosis and other hematologic conditions. The firm listed that its first two commercialized products are Andexxa^® and Bevyxxa^® (betrixaban), and that it is also advancing and developing cerdulatinib, a SYK/JAK inhibitor for use in treatment of hematologic cancers.

Portola Pharmaceuticals started off the day with a market capitalization of around $609.0 million with approximately 78.5 million shares outstanding and a short interest of about 23.0%. PTLA shares opened 130% higher today at $17.85 (+$10.09, +130.03%) over yesterday's $7.85 closing price. The stock has traded today between $17.71 and $17.91 per share and is currently trading at $17.83 (+$10.07, +129.77%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Trees form a valuable part of green infrastructure in cities by helping reduce surface water runoff, recent research finds. Together with grassy areas, significant reductions in surface water flows can be achieved by planting trees, reducing the risk of floods.

Groundwater is the earth’s largest freshwater resource and is vital for irrigation and global food production. In dry periods farmers pump groundwater to water crops, this is already happening at an unsustainable level in many places — exceeding the rate at which rain and rivers can refill the groundwater stores. This study seeks to identify where groundwater pumping is affecting stream flows and estimates where and when environmentally critical stream flows — required to maintain healthy ecosystems — can no longer be sustained.

A hacking group has started to flood a dark web hacking marketplace with databases containing a combined total of 73.2 million user records over 11 different companies. [...]